Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMP in Relapsed or Refractory Myeloma
NCT02468687Phase 1Completed
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Aug 2015
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of n-methyl-pyrrolidone in multiple myeloma (MM), sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Aug 2015; status: completed.
02
Drugs
n-methyl-pyrrolidone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02468687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02468687.